Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies
Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema. Read More
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact. Read More
Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer
Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment. Read More
Innovent secures NMPA approval for SYCUME, China’s first IGF-1R antibody for thyroid eye disease
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for SYCUME (teprotumumab N01), marking a major milestone in the treatment of thyroid ... Read More
Innovent begins IBI363 pivotal study in melanoma immunotherapy
Innovent Biologics, Inc. (HKEX: 01801), a global biopharmaceutical company specializing in innovative oncology therapies, has dosed the first patient in the IBI363 pivotal study, marking ... Read More
Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate
Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the development of IBI3009, a novel DLL3-targeted antibody-drug ... Read More
Innovent, Hutchmed announce conditional approval for cancer drug combination therapy
Innovent Biologics and Hutchmed (china) limited have received conditional nmpa approval for the combination therapy of tyvyt (sintilimab injection) and elunate (fruquintinib) for treating advanced ... Read More
Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell therapies and antibody products, have announced a ... Read More
FDA grants fast track designation to Innovent Biologics’ IBI343 in PDAC
Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical firm recognized for its innovative medicines, announced a pivotal advancement for its novel anti-CLDN18.2 ADC therapy, IBI343. ... Read More
Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: ... Read More